Literature DB >> 33983592

Breast Cancer-Related Low Penetrance Genes.

Daehee Kang1, Ji-Yeob Choi2.   

Abstract

Susceptibility genes involved in disease etiology and prognosis are categorized into two groups: high penetrance genes (i.e., BRCA1, CHEK2, ATM, etc.) and low penetrance genes (i.e., NATs, GSTs, CYPs, etc., and variants identified by genome-wide association studies). Since low penetrance genes have high population attributable risk, the usefulness of those genes to research on breast cancer prevention is not small. In this chapter, the previous studies on low-penetrance genetic susceptibility through a candidate gene approach and genome-wide association of breast cancer were summarized. The contribution of low-penetrance susceptibility genes to the breast cancer risk prediction models will also be discussed on the utility in clinical or public health application.

Entities:  

Keywords:  Genetic susceptibility; Genome-wide association study; High-penetrance genes; Low-penetrance genes; Polygenic risk score; Prediction model; Risk assessment

Mesh:

Year:  2021        PMID: 33983592     DOI: 10.1007/978-981-32-9620-6_22

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  52 in total

Review 1.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.

Authors:  Ben Zhang; Alicia Beeghly-Fadiel; Jirong Long; Wei Zheng
Journal:  Lancet Oncol       Date:  2011-04-20       Impact factor: 41.316

2.  Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients.

Authors:  Minghua Ji; Jinhai Tang; Jianhua Zhao; Bin Xu; Jianwei Qin; Jianwei Lu
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

Review 3.  Genetic epidemiology of breast and ovarian cancers.

Authors:  B Newman; R C Millikan; M C King
Journal:  Epidemiol Rev       Date:  1997       Impact factor: 6.222

4.  The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.

Authors:  Eunyoung Kang; Moon-Woo Seong; Sue K Park; Jong Won Lee; Jihyoun Lee; Lee Su Kim; Jeong Eon Lee; Sung Yong Kim; Joon Jeong; Sang Ah Han; Sung-Won Kim
Journal:  Breast Cancer Res Treat       Date:  2015-04-12       Impact factor: 4.872

Review 5.  Breast cancer susceptibility testing: past, present and future.

Authors:  Jessica I Goldberg; Patrick I Borgen
Journal:  Expert Rev Anticancer Ther       Date:  2006-08       Impact factor: 4.512

6.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

7.  Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.

Authors:  Soo-Youn Lee; Seock-Ah Im; Yeon Hee Park; Sook Young Woo; Seonwoo Kim; Moon Ki Choi; Wonjin Chang; Jin Seok Ahn; Young-Hyuck Im
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

8.  Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS).

Authors:  Ji-Eun Kim; Jaesung Choi; JooYong Park; Chulbum Park; Se Mi Lee; Seong Eun Park; Nan Song; Seokang Chung; Hyuna Sung; Wonshik Han; Jong Won Lee; Sue K Park; Mi Kyung Kim; Dong-Young Noh; Keun-Young Yoo; Daehee Kang; Ji-Yeob Choi
Journal:  Pharmacogenomics J       Date:  2018-04-04       Impact factor: 3.550

Review 9.  10 Years of GWAS Discovery: Biology, Function, and Translation.

Authors:  Peter M Visscher; Naomi R Wray; Qian Zhang; Pamela Sklar; Mark I McCarthy; Matthew A Brown; Jian Yang
Journal:  Am J Hum Genet       Date:  2017-07-06       Impact factor: 11.025

10.  ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Authors:  Hee-Jun Kim; Seock-Ah Im; Bhumsuk Keam; Hye Seon Ham; Kyung Hun Lee; Tae Yong Kim; Yu Jung Kim; Do-Youn Oh; Jee Hyun Kim; Wonshik Han; In-Jin Jang; Tae-You Kim; In Ae Park; Dong Young Noh
Journal:  Cancer Sci       Date:  2014-12-08       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.